pancreatic cancer

[Archives of Pharmacal Research] Researchers evaluated the anticancer effect of ACY-241, an HDAC6-selective inhibitor, on erlotinib-resistant pancreatic cancer cells that overexpressed HDAC6.

[Cell Chemical Biology] To enable tumor-localized immunotherapy following intravenous administration, investigators chemically conjugated a polyspecific integrin-binding peptide (PIP) to an immunostimulant to generate a tumor-targeted immunomodulatory agent, referred to as PIP-CpG.

[Molecular Cancer Research] Researchers identified the cell surface binding partner of Reg4 and dissected its role in colorectal cancer (CRC) and pancreatic cancer (PC) growth and stem cell survival. In vitro models of human CRC and PC were used to evaluate the results.

[iScience] Researchers examined the proliferation and drug resistance effect of ADP-ribosylation factor like-4c (Arl4c) on pancreatic cancer cells. They explored the contribution of Arl4c high expression in pancreatic stellate cell activation.

[Kintor Pharmaceutical Limited] Kintor Pharmaceutical Limited announced that the company has enrolled and dosed its first patient with advanced or refractory solid tumors in a clinical trial of ALK-1 antibody in combination with KN046.

[Cancer Chemotherapy and Pharmacology] RNA sequencing experiments were conducted on PANC-1 human pancreatic cancer cells treated with Docosahexaenoyl difluorodeoxycytidine (DHA–dFdC), dFdC, or vehicle control in vitro.